elosulfase alfa (vimizim) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA First in Class Fast Track FDA

Active Ingredient History

  • Now
Elosulfase alfa, sold under the brand name Vimizim, is a medication used for the treatment of Morquio syndrome which is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Elosulfase alfa is a synthetic version of this enzyme.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$875.1100 - $1156.6400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

bmn-100 | bmn 110 | bmn-110 | ec | elosulfase alfa | galactosamine (n-acetyl)-6-sulfate sulfatase, human | galactose-6-sulfate sulfatase, human | galnac6s protein, human | galns protein, human | morquio syndrome protein, human | mucopolysaccharidosis type iva protein, human | n-acetylgalactosamine-6-sulfatase | n-acetylgalactosamine-6-sulfatase, human | rhgalns | vimizim | vimzim


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue